Penn Vet has strong immunology research programs focusing on understanding basic immunologic mechanisms and how to develop new therapeutics for controlling disease.
Several Penn Vet immunologists investigate how pathogens interact with the immune system. Many of these laboratories focus on the study of parasites.
- Dr. Chris Hunter’s laboratory is devoted to defining the immune cells and cytokines that contribute to either the resolution of infection or the immunopathology caused by the protozoan parasite, Toxoplasma gondii.
- Studies in Dr. Phil Scott‘s laboratory involve understanding how memory T cells develop in order to design vaccines for a wide range of diseases, including leishmaniasis, as well as defining mechanisms used by the Leishmania parasites to evade the immune response.
- Dr. Igor Brodsky's research focuses on the interplay of bacterial virulence mechanisms and host innate immune recognition strategies. In particular, the Brodsky lab is interested in understanding how bacterial pathogens are detected by host cells as well as strategies utilized by bacterial pathogens to evade innate immune recognition.
- Dr. Oliver Garden, the Henry and Corinne R. Bower Professor of Medicine and Chair of the Department of Clinical Sciences & Advanced Medicine, is the principal investigator of the Garden Immune Regulation Laboratory at the School of Veterinary Medicine (Penn Vet). The Garden Immune Regulation Laboratory has expertise in two key areas: (1) the biology of regulatory cells of lymphoid and myeloid origin in the context of the cancer microenvironment and autoimmune disease, particularly myasthenia gravis, immune-mediated hemolytic anemia, and other immune-mediated diseases; and (2) the development of antigen-specific vaccinal immunotherapies for antibody-mediated autoimmune diseases, including myasthenia gravis and anti-N-methyl D-aspartate receptor encephalitis.
- In the clinics, Dr. Dan Morris studies hypersensitivity to fungus in dogs.
- In Dr. Oriol Sunyer’s laboratory there is a specific focus on understanding the role of the complement system of teleost fish in innate and adaptive immunity, and elucidating the evolutionary history of the components, molecular pathways and cells involved in these ancient immune processes. This research has direct implications in the development of new molecular adjuvants that will be useful in fish.
- Understanding the basic mechanisms that shape the immune response to tumors has direct implications for the development of new therapies for cancer. Dr. Mike Atchison’s laboratory explores the functions of a number of transcription factors that regulate immunoglobulin gene expression and that play important roles in lineage differentiation, embryonic development, and in oncogenesis.
- Protein ubiquitination and degradation have emerged as important mechanisms in regulating cell growth and survival that play a key role in cancer, and Dr. Serge Fuch’s laboratory currently focuses on the disregulated proteolysis of cytokine and hormone receptors in human malignant melanomas and breast cancers.
- In Dr. Bruce Freedman’s laboratory the main focus is signaling pathways that regulate lymphocyte and macrophage development and function, work that has ramifications in understanding immune responses to both infections and tumors.
- Dr. Carolina López's research centers on understanding the processes that lead to the generation of the immune response against viruses. In particular, her group studies early events following virus-host interaction that determine the successful transition from the less specific initial innate immune response to the more specific and persistent adaptive immune response.
- Recent sequencing of the canine genome has revealed a close phylogenetic relationship between man and dog and both species spontaneously develop cancers that have similar biological, behavioral and genetic characteristics. Dr.Nicola Mason’s laboratory focuses on the bench to bedside development of novel immunotherapeutic strategies to augment cytotoxic T cell responses against common cancers in domestic dogs. Evaluation of the safety and efficacy of novel therapeutic approaches used to treat privately owned dogs with advanced cancers aims to provide important pre-clinical data for human cancer patients as well as develop novel therapies for canine cancer patients.